Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $51M (down 3.9% year over year) with net income of −$63M.
Q2 2026 key financials · XBRL
- Revenue
- $51M
- −3.9% YoY · −2.3% QoQ
- Net income
- −$63M
- −129.8% YoY · −28.7% QoQ
- Operating margin
- -126.3%
- EPS (diluted)
- −$1.04
- −126.1% YoY · −26.8% QoQ
Source: XBRL data from the Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 10-Q on SEC EDGAR. USD.
Vanda Pharmaceuticals Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $50.5M, down 4% YoY from $52.6M
- Fanapt sales $36.0M, up 23% YoY; strongest product performance
- HETLIOZ sales $5.6M, down 66% YoY; weakest product performance
- NEREUS sales $1.0M following May 2026 U.S. launch
- Near-term outlook: BYSANTI launch expected second half of 2026; NEREUS demand and returns constrain revenue
Risk Factors
- New tariff risk triggered by April 2, 2026 proclamation imposing 100% duties on certain pharmaceutical and API imports
- Manufacturing dependence on foreign third parties could increase costs and reduce margins if exemptions do not apply
- Regulatory replacement risk from FDA approval requirements for chemistry, manufacturing and controls changes
- Supply-chain disruption risk from limited alternative manufacturers and lengthy supplier replacement processes
- Carried-forward risk factors otherwise unchanged from the December 31, 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vanda Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.